$8m placement and share purchase plan
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The funds raised will support clinical trial preparations and licensing discussions for Syntara's lead asset, amsulostat, in treating myelofibrosis. Eligible shareholders will have the opportunity to participate in the share purchase plan to raise additional funds without incurring transaction costs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Syntara
- Continuation of trading halt
- Positive FDA feedback for Amsulostat P2b trial
- Half Year Report and Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
- Amsulostat and Garvan in MRFF funded pancreatic trial
Later from Syntara
- Share Purchase Plan Offer Booklet
- Results of Share Purchase Plan
- Encouraging SNT-4728 Phase 2 iRBD results
- Appendix 4E and Annual Report
- Syntara expands SNT-9465 skin scarring study
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara